Oruka Therapeutics (ORKA) Return on Capital Employed (2011 - 2024)
Oruka Therapeutics' quarterly Return on Capital Employed came in at 26.85% in Q2 2024, down 716.0% year-on-year from 4.36% in Q3 2023, and down 20.11% quarter-over-quarter from 22.36% in Q1 2024.
Oruka Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 26.85% in Q2 2024.
- For the quarter ending Q2 2024, Return on Capital Employed fell 716.0% year-over-year to 26.85%; the trailing twelve-month figure through Jun 2024 stood at 26.85% (down 716.0% YoY), and the FY2023 full-year result was 18.32%, up 382.0% from the prior year.
- Return on Capital Employed for Q2 2024 stood at 26.85%, down from 22.36% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.53% in Q3 2023, with the low at 78.51% in Q1 2020.
- Average Return on Capital Employed over 5 years is 30.86%, with a median of 24.98% recorded in 2021.
- Year-over-year, Return on Capital Employed tumbled 6803 bps in 2020 and jumped 5650 bps in 2021.
- Tracing ORKA's Return on Capital Employed over 5 years: stood at 20.47% in 2020, then sank by 75 bps to 35.77% in 2021, then soared by 31 bps to 24.7% in 2022, then rose by 22 bps to 19.26% in 2023, then slumped by 39 bps to 26.85% in 2024.
- The last three Return on Capital Employed figures came in at 26.85% (Q2 2024), 22.36% (Q1 2024), and 19.26% (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -26.85% |
| Mar 31, 2024 | -22.36% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -18.53% |
| Jun 30, 2023 | -19.69% |
| Mar 31, 2023 | -22.07% |
| Dec 31, 2022 | -24.70% |
| Sep 30, 2022 | -33.03% |
| Jun 30, 2022 | -36.13% |
| Mar 31, 2022 | -36.84% |
| Dec 31, 2021 | -35.77% |
| Sep 30, 2021 | -31.52% |
| Jun 30, 2021 | -25.26% |
| Mar 31, 2021 | -22.01% |
| Dec 31, 2020 | -20.47% |
| Sep 30, 2020 | -19.54% |
| Jun 30, 2020 | -62.96% |
| Mar 31, 2020 | -78.51% |
| Dec 31, 2019 | -69.91% |
| Sep 30, 2019 | 4.31% |
| Jun 30, 2019 | -0.31% |
| Mar 31, 2019 | -10.49% |
| Dec 31, 2018 | -24.35% |
| Sep 30, 2018 | 18.58% |
| Jun 30, 2018 | -12.30% |
| Mar 31, 2018 | -43.09% |
| Dec 31, 2017 | -50.00% |
| Sep 30, 2017 | -128.44% |
| Jun 30, 2017 | -115.35% |
| Mar 31, 2017 | -86.24% |
| Dec 31, 2016 | -68.48% |
| Sep 30, 2016 | -54.37% |
| Jun 30, 2016 | -41.11% |
| Mar 31, 2016 | -34.48% |
| Dec 31, 2015 | -29.01% |
| Sep 30, 2015 | -25.66% |
| Jun 30, 2015 | -37.22% |
| Mar 31, 2015 | -74.07% |
| Dec 31, 2014 | -61.75% |
| Sep 30, 2014 | -54.35% |
| Jun 30, 2014 | -46.46% |
| Mar 31, 2014 | -44.05% |
| Dec 31, 2013 | -41.78% |
| Sep 30, 2013 | -10.55% |
| Jun 30, 2013 | -10.49% |
| Mar 31, 2013 | -41.26% |
| Dec 31, 2012 | -49.84% |
| Sep 30, 2012 | -152.49% |
| Jun 30, 2012 | -155.68% |
| Mar 31, 2012 | -127.82% |
| Dec 31, 2011 | -128.11% |
| Sep 30, 2011 | -117.45% |